logo
Plus   Neg
Share
Email

AbbVie: VENCLYXTO Plus Rituximab Gets Europe Approval To Treat CLL Patients

AbbVie Inc. (ABBV), a research-based global biopharmaceutical company, announced Thursday that it has received European Commission approval of VENCLYXTO (venetoclax) Plus Rituximab for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or R/R CLL who have received at least one prior therapy.

This approval allows more patients to receive VENCLYXTO in the second-line setting and gives healthcare providers the ability to prescribe this medicine to a broader population of patients with R/R CLL than the previously approved indication for VENCLYXTO as monotherapy in the European Union. The approval is valid in all 28 member states of the EU, as well as Iceland, Liechtenstein and Norway.

VENCLYXTO is being developed by AbbVie and Roche (RHHBY). It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S.

The company noted that the EC approval is based on results from the MURANO Phase 3 randomized clinical trial, which evaluated the efficacy and safety of VENCLYXTO in combination with rituximab compared to bendamustine in combination with rituximab, an established standard of care chemoimmunotherapy regimen for patients with R/R CLL.

CLL is a slow-growing form of leukemia, or blood cancer, in which too many immature lymphocytes are found predominantly in the blood and bone marrow.

In September 2018, AbbVie announced the European Committee for Medicinal Products for Human Use or CHMP granted a positive opinion for the Marketing Authorization Application for VENCLYXTO plus rituximab for the treatment of patients with R/R CLL.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Microsoft Corp. (MSFT) founder Bill Gates has admitted that his greatest mistake was allowing Google's android to become a dominant mobile operating system. Speaking at a Economic Club of Washington luncheon, Gates said to David Rubinstein on Monday, "We're in the field of doing operating systems... McDonald's said Monday that the introduction of fresh beef at its restaurants just over one year ago has helped it gain market share in the informal eating out or IEO category for the first time in five years. In May 2018, the burger chain switched to fresh beef quarter-pound burgers from frozen beef across the U.S., as part of its efforts to provide customers with a "hotter, juicer burger." 'Toy Story 4' has broken global office box records for an animated movie, according to media reports. The movie is the fourth instalment in the 'Toy Story' series and is the sequel to 2010's 'Toy Story 3.' The Disney and Pixar film has reportedly earned $238 million after opening worldwide over the weekend and performed particularly well in Latin America and Europe.
Follow RTT